IA
LCTX icon

IndexIQ Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

IndexIQ Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-781,328
Closed -$715K – 640
2018
Q4 		$715K Sell
781,328
-184,589
-19% -$283K 0.02% 451
2018
Q3 		$1.98M Buy
965,917
+36,482
+4% +$76.6K 0.06% 343
2018
Q2 		$1.67M Sell
929,435
-7,290
-0.8% -$14.7K 0.05% 416
2018
Q1 		$2.17M Buy
936,725
+470,027
+101% +$1.1M 0.07% 184
2017
Q4 		$878K Buy
466,698
+179,546
+63% +$392K 0.03% 418
2017
Q3 		$713K Buy
287,152
+130,305
+83% +$323K 0.03% 392
2017
Q2 		$431K Buy
+156,847
New +$438K 0.02% 387

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return